Search

Your search keyword '"Anthrax Vaccines"' showing total 32 results
Start Over Descriptor "Anthrax Vaccines" Journal plus company updates
32 results on '"Anthrax Vaccines"'

1. Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease

Subjects
United States. Food and Drug Administration, Anthrax vaccines, Intravenous immunoglobulins, Smallpox vaccines, Drug approval, Botulism, Vaccines, Biological products, Vaccinia, Backup software, Production management, Diseases, Infrastructure (Economics), General interest, News, opinion and commentary
Abstract

GAITHERSBURG: Emergent BioSolutions Inc has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has initiated development of two product candidates for the treatment and prevention [...]

Published
2020

2. BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine

Subjects
United States. Food and Drug Administration, United States. National Institutes of Health, United States. National Institute of Allergy and Infectious Diseases, Clinical trials, Anthrax vaccines, Medical research, Biological products industry -- Product development, Vaccines, Allergy, Health, Communicable diseases, General interest, News, opinion and commentary
Abstract

ANN ARBOR: BlueWillow Biologics has issued the following press release: BlueWillow Biologics(r), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new [...]

Published
2019

4. Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile

Subjects
Anthrax vaccines, Vaccines, Purchasing, Prophylaxis, Industrial research, Contract agreement, General interest, News, opinion and commentary
Abstract

Maryland: Emergent BioSolutions has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option [...]

Published
2019

5. Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile

Subjects
United States. Food and Drug Administration -- Planning, Anthrax vaccines, Business planning, Purchasing, Vaccines, Industrial research, Company business planning, General interest, News, opinion and commentary
Abstract

Rockville: Emergent BioSolutions, Inc. (EBS) has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the company [...]

Published
2019

7. Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries

Subjects
Anthrax vaccines, General interest, News, opinion and commentary, European Union
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for market authorization of BioThrax(r) [...]

Published
2018

8. Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries

Subjects
Anthrax vaccines, General interest, News, opinion and commentary, European Union
Abstract

GAITHERSBURG, Md, USA: Emergent BioSolutions Inc. has issued the following press release: -Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for market authorisation [...]

Published
2018

9. Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update

Subjects
Anthrax vaccines, Influenza vaccines, Company earnings/profit, General interest, News, opinion and commentary
Abstract

Gaithersburg: Altimmune, Inc. has issued the following press release: Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December 31, 2017. Corporate Highlights Enrolled [...]

Published
2018

10. Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program

Subjects
United States. Biomedical Advanced Research and Development Authority, United States. National Institute of Allergy and Infectious Diseases, Clinical trials, Anthrax vaccines, Medical research, General interest, News, opinion and commentary
Abstract

Gaithersburg: Altimmune, Inc. has issued the following press release: Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced data from a pre-clinical study comparing SparVax-L and BioThrax(r) against anthrax infection. [...]

Published
2018

11. Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial

Subjects
United States. Food and Drug Administration, Anthrax vaccines, Drug approval, General interest, News, opinion and commentary
Abstract

Coral Gables:Catalyst Pharmaceuticals, Inc.has issued the following press release: Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the Company has submitted an Investigational New Drug (IND) application to the [...]

Published
2017

12. Company Profile of Glide Pharma

Subjects
Anthrax vaccines, Influenza vaccines, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

Oxfordshire: Follwing is the Company Profile of Glide Pharma: Glide Technologies is a clinical stage development company focused on solid dose formulations of therapeutics and vaccines. Glide has a growing [...]

Published
2017

13. NanoBio and Porton Biopharma Receive Approval to Advance Next Generation Anthrax Vaccine

Subjects
United States. National Institute of Allergy and Infectious Diseases, Clinical trials, Antigens, Anthrax vaccines, Medical research, Biological products industry, General interest, News, opinion and commentary
Abstract

Ann Arbor, MI: NanoBio has issued the following press release: NanoBio Corporation today announced the progression of a novel intranasal anthrax vaccine into a pre-clinical IND-enabling toxicology study funded by [...]

Published
2017

14. NanoBio And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine

Subjects
United States. National Institute of Allergy and Infectious Diseases, Clinical trials, Antigens, Anthrax vaccines, Medical research, Biological products industry, General interest, News, opinion and commentary
Abstract

ANN ARBOR: NanoBio Corporation has issued the following press release: NanoBio Corporation today announced the progression of a novel intranasal anthrax vaccine into a pre-clinical IND-enabling toxicology study funded by [...]

Published
2017

18. Profile of John Troyer Vice President of PharmAthene, Inc

Subjects
PharmAthene Inc. -- Officials and employees, Anthrax vaccines, Social services, General interest, News, opinion and commentary
Abstract

Annapolis: Following is the Profile of John Troyer Vice President of PharmAthene, Inc: Dr. Troyer was appointed our Vice President, Product Development effective January, 2008. Between January 2002 and January [...]

Published
2017

19. Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax

Subjects
United States. Food and Drug Administration, Building permits, Anthrax vaccines, Independent regulatory commissions, General interest, News, opinion and commentary
Abstract

GAITHERSBURG: Emergent BioSolutions Inc has issued the following news release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, [...]

Published
2017

20. Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax

Subjects
United States. Food and Drug Administration, Building permits, Anthrax vaccines, Independent regulatory commissions, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, [...]

Published
2017

21. Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax

Subjects
United States. Food and Drug Administration, Building permits, Anthrax vaccines, Independent regulatory commissions, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, [...]

Published
2017

22. Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax

Subjects
United States. Food and Drug Administration, Building permits, Anthrax vaccines, Independent regulatory commissions, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, [...]

Published
2017

23. Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax

Subjects
United States. Food and Drug Administration, Building permits, Anthrax vaccines, Independent regulatory commissions, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, [...]

Published
2017

24. Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile

Subjects
United States. Food and Drug Administration -- Government finance, United States. Centers for Disease Control and Prevention -- Government finance, United States. Department of Health and Human Services -- Government finance, Anthrax vaccines, Anthrax -- Prevention, Biological products industry, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Department of Health and Human Services (HHS) is advancing its anthrax [...]

Published
2016

25. Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile

Subjects
United States. Food and Drug Administration -- Government finance, United States. Centers for Disease Control and Prevention -- Government finance, United States. Department of Health and Human Services -- Government finance, Anthrax vaccines, Anthrax -- Prevention, Biological products industry, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Department of Health and Human Services (HHS) is advancing its anthrax [...]

Published
2016

26. Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile

Subjects
United States. Food and Drug Administration -- Government finance, United States. Centers for Disease Control and Prevention -- Government finance, United States. Department of Health and Human Services -- Government finance, Anthrax vaccines, Anthrax -- Prevention, Biological products industry, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Department of Health and Human Services (HHS) is advancing its anthrax [...]

Published
2016

27. Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile

Subjects
United States. Food and Drug Administration -- Government finance, United States. Centers for Disease Control and Prevention -- Government finance, United States. Department of Health and Human Services -- Government finance, Anthrax vaccines, Anthrax -- Prevention, Biological products industry, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Department of Health and Human Services (HHS) is advancing its anthrax [...]

Published
2016

28. Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55

Subjects
United States. Food and Drug Administration, Anthrax vaccines, Drug approval, General interest, News, opinion and commentary
Abstract

Gaithersburg, Maryland: Emergent BioSolutions has issued the following news release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics [...]

Published
2016

29. Profile of John Troyer, Ph.D. Vice President of PharmAthene, Inc

Subjects
PharmAthene Inc. -- Officials and employees, Anthrax vaccines, Social services, General interest, News, opinion and commentary
Abstract

Annapolis: Following is the Profile of John Troyer, Ph.D. Vice President of PharmAthene, Inc: Dr. Troyer was appointed our Vice President, Product Development effective January, 2008. Between January 2002 and [...]

Published
2016

30. Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55

Subjects
United States. Food and Drug Administration, Anthrax vaccines, Drug approval, General interest, News, opinion and commentary
Abstract

Rockville: Emergent Biosolutions, Inc. has issued the following press release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics [...]

Published
2016

31. Pfenex Announces Positive Anthrax Vaccine Study Results

Subjects
Anthrax vaccines, General interest, News, opinion and commentary
Abstract

California: Pfenex Inc. has issued the following press release: Pfenex Inc. (NYSE MKT: PFNX) announced today positive immunogenicity and safety data from the Day 70 analysis of the Px563L anthrax [...]

Published
2016

32. FDA Completes Pre-Approval Inspection of Emergent BioSolutions' Large-Scale Manufacturing Facility for BioThrax

Subjects
United States. Food and Drug Administration, Anthrax vaccines, Drug approval, General interest, News, opinion and commentary
Abstract

Gaithersburg, Maryland: Emergent BioSolutions has issued the following news release: Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval Inspection (PAI) [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results